• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Vaccines, Blood & Biologics

  • Print
  • Share
  • E-mail

Section Contents Menu


Response to FDA Request of Oct 2, 2007- Cervavix, October 4, 2007

From: Edward.M.Yuhas@gsk.com
To: Gemignani, Helen S;
Subject: Cervavix; Response to FDA Request of Oct 2, 2007
Date: Thursday, October 04, 2007 11:09:12 AM
Attachments: HPV-009 request firewall_2Oct07.doc

Helen, At Matt Whitman's request, I am sending you a table that indicates the treatment assignments for the nine patients identified in your request of October 2, 2007. Please note that in the attached table the treatment the patients received was identified as either MPL or Non-MPL. MPL is equivalent to the term HPV and Non-MPL is equivalent to the term HAV. Please note that we will also submit this information to FDA in a 'formal' submission shortly. If you have any questions, I can be reached at 215-751-3836 Regards
"EMF <fda.hhs.gov>" made the following annotations.
This message was sent by GlaxoSmith Kline across the Internet in encrypted format and was successfully decrypted, unless otherwise noted. Glaxo Wellcome